NSE · HEXAGON · Consumer Defensive
Hexagon Nutrition Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹98 Cr with net profit ₹14 Cr — a 13.84% net margin, versus 12.06% the period before.
Shareholding
As of 2026-06-30
- Promoter64.29%
- Public28.99%
- FII0.29%
- DII6.43%
20,187 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.63× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ESM · ESM 1. Trading may carry price bands, periodic call auction or higher margins.
- Promoter holding fell 25.11 percentage points to 64.29% in the latest disclosure.
Peer comparison
Packaged Foods · ranked #3 of 9 by market cap · medians across 4 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Tasty Bite Eatables Ltd. | ₹2,323 Cr | 65.07 | 6.79 | 10.32% | 6.45% |
| Regaal Resources Limited | ₹836 Cr | 13.81 | 1.71 | 11.35% | 4.9% |
| Hexagon Nutrition Limited(this company) | ₹772 Cr | 20.45 | 2.67 | 16.26% | 0% |
| Sheetal Cool Products Ltd. | ₹579 Cr | 30.27 | 3.69 | 12.18% | 5.22% |
| Nakoda Group of Industries Ltd. | ₹70 Cr | 43.11 | 2.43 | 5.19% | 3.63% |
AI analysis
AI-generated · google/gemini-2.5-flashHexagon Nutrition Limited is listed with a market capitalization of Rs 853 Cr. The company operates as a nutraceutical business, focusing on the development and supply of micronutrient premixes, clinical nutrition, and therapeutic food. It serves food companies and the nutraceutical industry in India and internationally, including South Africa, Malaysia, and various other countries. The company offers a range of products including ready-to-use supplementary food (RUSF) and ready-to-use therapeutic food (RUTF).
Positives
- +Revenue grew by 8% to Rs 382.63 Cr for the fiscal year.
- +The debt-to-equity ratio is low at 0.17.
- +Return on Capital Employed (ROCE) is 20.71%.
Negatives
- −The net profit margin for the fiscal year ended March 2025 was 0%.
- −Promoter holding decreased from 89.40% in May 2026 to 64.29% in June 2026.
- −The company is currently under ESM surveillance.
Business Overview
Hexagon Nutrition Limited specializes in nutraceuticals, providing micronutrient premixes, clinical nutrition, and therapeutic food products. Its offerings include health and wellness products, home fortification solutions, and various functional foods and dietary supplements. The company's products cater to specific health needs, such as managing lifestyle disorders, and are supplied to food companies and the wider nutraceutical industry across numerous geographies including India, South Africa, and Malaysia.
Financial Performance
For the fiscal year ending March 2025, Hexagon Nutrition Limited reported revenue of Rs 331.287 Cr, marking an 8% increase in revenue growth. The company posted a net profit of Rs 24.377 Cr for the same period. In the most recent quarter ending March 2026, revenue was Rs 115.04 Cr with a net profit of Rs 10.9 Cr.
Profitability & Returns
Hexagon Nutrition Limited's Return on Equity (ROE) stands at 16.26%, and Return on Capital Employed (ROCE) is 20.7063%. The company's Earnings Per Share (EPS) for the fiscal year ending March 2025 was Rs 1.98. For the same period, the company's net profit margin was 0%.
Balance Sheet
The debt-to-equity ratio for Hexagon Nutrition Limited is 0.17, indicating relatively low leverage. The book value per share is Rs 23.48. No dividend yield was reported.
Ownership & Pledges
As of June 30, 2026, the promoter holding in Hexagon Nutrition Limited was 64.29%. Public shareholding stood at 28.9932%. Institutional investors, including DIIs and FIIs, held 6.7168% of the company's shares, with DIIs holding 6.4286% and FIIs holding 0.2882%. There were no promoter pledges reported.
Regulatory & Surveillance
Hexagon Nutrition Limited is currently under ESM surveillance. The company is subject to ESM measures, which typically involve enhanced monitoring by regulatory bodies due to specific criteria being met.
Data as of — price: 2026-07-30 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.